Sanofi’s dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
Stable profits, low leverage to keep credit profiles comfortable
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
ALS patients experience neuroinflammation and rapid neurodegeneration
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
Subscribe To Our Newsletter & Stay Updated